Form 4: Establishment Labs Director Ann Custin Receives Equity Award

Establishment Labs Holdings Inc. Director Ann Custin was granted 3,413 common shares as an equity award under the company's 2018 Equity Incentive Plan.

Summary

• Ann Custin, a Director of Establishment Labs Holdings Inc. (ESTA), received an equity award of 3,413 common shares on May 23, 2025.
• The shares were granted at a price of $0, indicating a stock unit award rather than a purchase.
• This award was made under the Issuer's 2018 Equity Incentive Plan.
• Following this transaction, Ann Custin beneficially owns a total of 20,074 common shares.
• The awarded shares are scheduled to vest in full on the earlier of May 23, 2026, or the day prior to the Issuer's next annual meeting of stockholders, contingent on Ms. Custin continuing as a service provider through such date.

Sentiment

Score: 7

Explanation: The document reports a standard equity grant to a director, which is generally viewed positively as it aligns interests. There are no negative financial implications or unusual events reported.

Positives

• The grant of equity to a director aligns their long-term interests with those of the company's shareholders.
• The award is part of an established 2018 Equity Incentive Plan, indicating a structured and routine compensation approach for key personnel.

Risks

• The vesting of the awarded shares is conditional upon Ann Custin's continued service as a director until the specified vesting date, meaning the shares could be forfeited if her service ceases prematurely.

Future Outlook

The awarded shares are subject to future vesting, contingent on the director's continued service until May 23, 2026, or the day prior to the next annual meeting of stockholders.

Management Comments

• The filing is signed by Rajbir S. Denhoy, Chief Financial Officer, by power of attorney, indicating standard corporate procedure for such filings.

Industry Context

This transaction is a routine insider filing (Form 4) for an equity grant to a director, which is a common practice in publicly traded companies across various sectors, including medical aesthetics, to align management and director interests with shareholders. Such compensation structures are typical for companies in this industry.

Comparison to Industry Standards

• Equity grants to directors are a standard compensation practice across various industries, including medical devices and aesthetics, to incentivize long-term commitment and performance.
• The use of a pre-existing 2018 Equity Incentive Plan suggests a formal and established compensation framework, consistent with corporate governance best practices for public companies.
• The vesting schedule (one year or next annual meeting) is a common approach for director equity awards, balancing retention with performance alignment.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grant aligns the director's interests with shareholders, potentially fostering long-term value creation.
• Employees: No direct impact on general employees mentioned, but it reflects the company's compensation philosophy for key personnel.

Next Steps

• The awarded shares will vest on the earlier of May 23, 2026, or the day prior to the Issuer's next annual meeting of stockholders, subject to continued service.

Key Dates

Recommendation

Keywords

Establishment Labs Holdings Inc., ESTA, Form 4, SEC filing, insider transaction, equity award, stock grant, director compensation, stock units, incentive plan